17 September, 2026
In a landmark decision that promises to reshape the landscape of chronic disease management across the continent, Members of the European Parliament (MEPs) have officially adopted the Public Health Committee’s comprehensive report on cardiovascular diseases. This legislative milestone serves as a decisive endorsement of a holistic, integrated approach to non-communicable diseases (NCDs), signaling a shift away from siloed medical interventions toward a unified strategy focused on prevention, early detection, and long-term patient wellbeing.
The report, developed in direct response to the European Commission’s ambitious "Safe Hearts Plan," marks the culmination of months of rigorous policy debate. By formally recognizing the intrinsic, often inseparable link between cardiovascular and respiratory health, the Parliament has laid the groundwork for a more resilient healthcare architecture in Europe—one that prioritizes the patient experience over traditional diagnostic boundaries.
The Core Mandate: Main Facts of the Legislative Shift
The adopted report is not merely a policy statement; it is a strategic blueprint designed to tackle the leading causes of morbidity and mortality in the European Union. At its core, the initiative seeks to move beyond the reactive treatment of acute cardiac events and address the systemic precursors of NCDs.
The document mandates that EU Member States harmonize their approaches to health screening. Key pillars of this initiative include:
- Integrated Screening Pathways: Moving away from isolated heart-health checks to comprehensive assessments that include respiratory function tests, specifically targeting high-risk populations.
- Comorbidity Management: A formal recognition that conditions such as Chronic Obstructive Pulmonary Disease (COPD) and Obstructive Sleep Apnoea (OSA) are not just comorbidities but are fundamentally intertwined with cardiovascular outcomes.
- Prevention and Inequality: A commitment to addressing the socio-economic determinants of health, acknowledging that cardiovascular and respiratory health outcomes are deeply shaped by regional inequalities and disparities in access to care.
By codifying these requirements, the European Parliament is effectively forcing a redesign of national health programs, compelling ministries across the EU to integrate their cardiovascular and respiratory monitoring infrastructure.
Chronology of a Policy Transformation
The journey to this week’s vote reflects a growing consensus among scientific communities and political stakeholders that the status quo of European healthcare delivery was failing to keep pace with the burden of chronic disease.
- Q1 2025: The Commission’s Call to Action. The European Commission unveils the Safe Hearts Plan, a high-level policy document aimed at reducing the burden of cardiovascular disease (CVD) by 2030. While initially centered on cardiology, the plan opened the door for broader health policy discourse.
- Late 2025: The ERS Advocacy Push. The European Respiratory Society (ERS) and the European Lung Foundation (ELF) began a sustained advocacy campaign. They argued that any plan focused on the "heart" that ignored the "lungs" would be fundamentally flawed, given the shared risk factors like smoking, air pollution, and sedentary lifestyles.
- Q2 2026: Public Health Committee Deliberations. The European Parliament’s Public Health Committee began drafting its report. During this period, intense lobbying from scientific bodies ensured that respiratory health was woven into the legislative text.
- July 2026: The "EU Screening Week" Initiative. The ERS launched a series of lung-testing events across Europe, providing real-world evidence to MEPs that simple, standardized respiratory screenings could be easily integrated into existing cardiovascular diagnostic workflows.
- 17 September 2026: The Plenary Vote. The European Parliament officially adopts the report, signaling a transition from advocacy to implementation.
Supporting Data: Why Integration is Non-Negotiable
The urgency behind this legislative shift is supported by mounting clinical data. The ERS, in its briefing to MEPs, highlighted that the prevalence of "multimorbidity"—the presence of two or more chronic conditions—is rising rapidly across the aging European population.
The Interdependency of Heart and Lung
Clinical studies have consistently demonstrated that patients with COPD are at a significantly higher risk of developing cardiovascular disease. The systemic inflammation caused by chronic respiratory obstruction places a heavy burden on the cardiovascular system. Conversely, patients with heart failure frequently present with undiagnosed respiratory conditions, which, if left untreated, exacerbate cardiac symptoms.
The Economic Case for Screening
Data presented during the parliamentary hearings suggests that the economic burden of NCDs in Europe is reaching a breaking point. By failing to detect respiratory issues early in patients presenting with cardiovascular risks, healthcare systems are spending billions on emergency admissions that could have been avoided. Integrating spirometry and respiratory risk assessments into standard heart checks is estimated to be highly cost-effective, with the potential to reduce hospital readmission rates by up to 15% within the first three years of implementation.
Official Responses and Strategic Vision
The reaction from the scientific community has been one of cautious optimism, viewing this vote as the beginning of a long-term collaborative effort.
ERS Perspective: A Call for Unified Action
Raquel Duarte, ERS Director of Scientific Affairs to the EU, articulated the significance of the vote during a press briefing following the announcement.
"This vote by the European Parliament marks an important step towards strengthening cardiovascular and respiratory health together," Duarte stated. "The Safe Hearts Plan provides a valuable framework for addressing cardiovascular disease, and importantly its comorbidities and precursors across the entire health pathway—from prevention and early detection to treatment and rehabilitation."
Duarte emphasized that the victory lies in the acknowledgment of the "patient journey." She noted that by addressing COPD and OSA within the framework of heart health, the EU is moving toward a patient-centered model that recognizes the whole person, rather than a single organ system.
Looking Toward Implementation
The focus now shifts from Brussels to the national capitals of the Member States. The ERS and its partners have made it clear that the legislation is only as good as its execution. "The next step now is to ensure that the Safe Hearts Plan translates into clear and effective measures across the EU," Duarte added. This will require unprecedented cooperation between national health ministries, the scientific community, and, crucially, the patients and civil society organizations who must hold their governments accountable to these new standards.
Implications: The Future of European Healthcare
The adoption of this report carries profound implications for the future of European public health policy.
1. Standardized Health Checks
Citizens across the EU can expect a shift in how they experience routine health check-ups. The integration of respiratory function assessment into cardiovascular screening will become the new "gold standard." This means that a person visiting a clinic for blood pressure monitoring or cholesterol screening will increasingly be offered lung function testing, ensuring a more comprehensive diagnostic profile.
2. A New Standard for Research Funding
This legislative shift will likely dictate the allocation of Horizon Europe research funding. Projects that prioritize "cross-disease" research—examining the intersection of heart and lung health—are set to receive preferential backing. This will catalyze a new wave of scientific innovation focused on the underlying mechanisms of chronic disease rather than just the symptoms.
3. Tackling Health Inequalities
By prioritizing the "risk factors" mentioned in the report, the Parliament is signaling that it is no longer sufficient to treat the affluent few. The mandate explicitly calls for programs that reach vulnerable populations, specifically addressing the environmental and social factors—such as poor housing, air quality, and smoking access—that contribute to the disproportionate burden of NCDs in certain demographics.
4. A Template for Other NCDs
While this report focuses on the nexus of cardiovascular and respiratory health, policy experts suggest this could serve as a template for other areas. By proving that integrated, cross-disciplinary health approaches work, the EU may look to apply similar frameworks to the links between diabetes, kidney health, and neurology.
Conclusion
The European Parliament’s decision on 17 September 2026, represents a maturation of European health policy. It acknowledges that in the 21st century, health is not a series of isolated biological events but a continuous spectrum of risk and resilience. As the Safe Hearts Plan transitions from a legislative document to a lived reality in clinics and hospitals across the continent, the focus will remain on the synergy between the heart and the lungs—a partnership that, if nurtured through early detection and integrated care, promises to add years to the lives of millions of Europeans.
The work ahead is significant, requiring the sustained political will of 27 Member States, but for the first time, the roadmap is clear. The era of the siloed approach is drawing to a close, replaced by a vision of health that is as holistic as the human body itself.
